RadHop-Net: A Lightweight Radiomics-to-Error Regression for False Positive Reduction In MRI Prostate Cancer Detection
Vasileios Magoulianitis, Jiaxin Yang, Catherine A. Alexander, C. -C. Jay Kuo
TL;DR
The paper tackles the high false-positive rate in bpMRI-based clinically significant prostate cancer detection. It proposes RadHop features for Stage 1 and RadHop-Net, a lightweight CNN trained in a radiomics-to-error fashion to predict a residue $\varepsilon$ that corrects Stage 1 probabilities. A novel wrMSE loss with $\gamma=0.95$ balances the learning between false positives and true positives. On the pi-cai dataset, the two-stage pipeline improves lesion-level AP from $0.407$ to $0.468$ and achieves AUROC $0.839$, with approximately $54{,}585$ parameters, illustrating a practical, low-complexity approach for FP reduction in MRI prostate cancer detection.
Abstract
Clinically significant prostate cancer (csPCa) is a leading cause of cancer death in men, yet it has a high survival rate if diagnosed early. Bi-parametric MRI (bpMRI) reading has become a prominent screening test for csPCa. However, this process has a high false positive (FP) rate, incurring higher diagnostic costs and patient discomfort. This paper introduces RadHop-Net, a novel and lightweight CNN for FP reduction. The pipeline consists of two stages: Stage 1 employs data driven radiomics to extract candidate ROIs. In contrast, Stage 2 expands the receptive field about each ROI using RadHop-Net to compensate for the predicted error from Stage 1. Moreover, a novel loss function for regression problems is introduced to balance the influence between FPs and true positives (TPs). RadHop-Net is trained in a radiomics-to-error manner, thus decoupling from the common voxel-to-label approach. The proposed Stage 2 improves the average precision (AP) in lesion detection from 0.407 to 0.468 in the publicly available pi-cai dataset, also maintaining a significantly smaller model size than the state-of-the-art.
